RxDoctor Payments Data

Mark Fleming, MD

Vascular Surgery · Sioux Falls, SDNPI 1841255932

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (33.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 45.9% of the total.

$54,647in general payments, 2019–2025

Across 219 payments — averaging $249.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$25K
  • Boston Scientific$23K
  • W. L. Gore & Associates, Inc.$3K
  • Silk Road Medical, Inc.$959
  • Bard Peripheral Vascular, Inc.$366
  • Penumbra, Inc.$342
  • plus $2K from 15 others
$81,770in research payments, 2019–2025

Across 47 payments — averaging $1739.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$61K
  • Abbott$18K
  • Medtronic$3K

What the payments were for

  • Consulting fees$18,48134%
  • Speaking & faculty fees$11,56321%
  • Travel & lodging$14,16726%
  • Food & beverage$10,43719%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular surgery providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$306,691
Medicare patients
891
Services billed
2,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$33,386
XareltoRivaroxaban35$20,293
ClopidogrelClopidogrel Bisulfate120$1,020
Atorvastatin Calcium61$561
Rosuvastatin Calcium50$509

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →